Japan to launch offshore "blue carbon" study for CO2 capture, storage
KYODO NEWS - 2 hours ago - 11:21 | All, Japan
The Japanese government will launch offshore "blue carbon" research aimed at capturing carbon dioxide through cultivated sea plants and storing it in the deep sea to accelerate decarbonization, sources familiar with the matter said Monday.
The government hopes these plants will play a key role in mitigating climate change, as CO2 is highly soluble in water, and marine vegetation grows by absorbing dissolved CO2. Coastal and ocean plants, such as mangroves and kelp, are known to absorb and store more carbon than terrestrial vegetation.
Blue carbon typically refers to carbon trapped in the deep sea after being captured by marine ecosystems through photosynthesis, while green carbon refers to carbon stored in terrestrial ecosystems such as forests.
The Environment Ministry will commission the Japan Agency for Marine-Earth Science and Technology, major oil distributor Eneos Corp., and others to study how seaweed behaves when submerged at considerable depths and to assess the environmental impact of such carbon capture and storage projects, according to the sources.
Although CO2 emissions in Japan have declined mainly due to the expansion of renewable energy and the restart of nuclear reactors, the government still needs to boost carbon capture efforts to achieve net zero emissions by 2050.
Japan relies heavily on forests to capture CO2, with about 45 million tons absorbed in fiscal 2023. However, their absorption capacity has been declining due to the aging of trees.
"If we can demonstrate a technology to enable CO2 fixation on the seafloor, it could be a significant source of (CO2) absorption," a senior official of the ministry said.
Japan aims to capture 1 million tons of CO2 by fiscal 2035 and 2 million tons by fiscal 2040 through blue carbon, compared with some 34 tons absorbed by coastal plants in fiscal 2023.
Related coverage:
Japan aims for all new vehicles to use biofuel by early 2030s
Japan to mull setting target of 60-66% emissions cut by FY 2035
Japan firms' plans for CO2 export, storage in Southeast Asia on rise
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Kyodo News
4 hours ago
- Kyodo News
Japanese startup test kit shows promise in early cancer detection
KYODO NEWS - 5 hours ago - 13:02 | All, Japan A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means. The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer. The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025. "We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse. The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others. Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May. Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ. Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company. In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
Kyodo News
9 hours ago
- Kyodo News
Japanese startup test kit shows promise in early cancer detection
KYODO NEWS - 3 hours ago - 10:02 | All, Japan A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means. The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer. The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025. "We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse. The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others. Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May. Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ. Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company. In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
The Mainichi
10 hours ago
- The Mainichi
Japanese startup test kit shows promise in early cancer detection
TOKYO (Kyodo) -- A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means. The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer. The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025. "We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse. The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others. Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May. Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ. Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company. In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
